StockData
Abivax S.A. logo

Abivax S.A. (ABVX) stock

ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 1/30
$80.65−3.18 (-3.79%)

Close on Nov 19, 2026Market cap $6.33BP/E –Yield –

Abivax free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Abivax's free cash flow for the twelve months ending Jun 30, 2026 was -€197.27M. For fiscal 2025 it was -€161.27M. The highest annual figure on record is -€45.10M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€161.27M–
FY2024Dec 31, 2024-€154.71M–
FY2023Dec 31, 2023-€97.40M–
FY2022Dec 31, 2022-€54.22M–
FY2021Dec 31, 2021-€45.10M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€52.10M–
Q1 FY2026Mar 31, 2026-€50.57M–
Q4 FY2025Dec 31, 2025-€23.32M–
Q3 FY2025Sep 30, 2025-€71.28M–
Q2 FY2025Jun 30, 2025-€33.36M–
Q1 FY2025Mar 31, 2025-€33.32M–
Q4 FY2024Dec 31, 2024-€33.61M–
Q3 FY2024Sep 30, 2024-€35.69M–
Q2 FY2024Jun 30, 2024-€50.65M–
Q1 FY2024Mar 31, 2024-€34.77M–

More Abivax figures

See a number that looks wrong?